CAMBRIDGE, Mass., May 27, 2003 (BUSINESS WIRE) -- Alkermes, Inc., (Nasdaq: ALKS) will host a conference call at 4:30pm EDT on Thursday, May 29, 2003 to discuss the Company's financial results for the year ending March 31, 2003. Management will review the year and provide an update on the company.
The conference call may be accessed by dialing 1-800-565-8107 for domestic callers and 1-703-464-5616 for international callers. The conference call ID number is 154991. Additionally, the call will be webcast on the investor relations section of Alkermes' website at www.alkermes.com and archived on the site until Monday, June 9, 2003 at 5:00pm.
A replay of the conference call will be available from 7:30pm EDT on May 29, 2003 through 11:59 pm EDT on June 2, 2003, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 907721.
Alkermes, Inc., is an emerging pharmaceutical company developing products based on its sophisticated drug delivery technologies to enhance therapeutic outcomes. Our areas of focus include: controlled, extended-release of injectable drugs utilizing our ProLease(R) and Medisorb(R) delivery systems and the development of inhaled pharmaceutical products based on our proprietary Advanced Inhalation Research, Inc., ("AIR(R)") pulmonary delivery system. Our business strategy is twofold. We partner our proprietary technology systems and drug delivery expertise with many of the world's finest pharmaceutical companies and also develop novel, proprietary drug candidates for our own account. In addition to our Cambridge, Massachusetts headquarters, research and manufacturing facilities, we operate research and manufacturing facilities in Ohio.
SOURCE: Alkermes, Inc.
Alkermes, Inc.Rebecca Peterson, 617/583-6378